Diabetic nephropathy (DN) is an important public health concern of increasing proportions and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the most common long-term microvascular complications of diabetes mellitus that is characterized by proteinuria and glomerular structural changes. LRG1 is a novel pro-angiogenic factors involved in the abnormal angiogenesis and renal fibrosis in DN.
Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.
Target:
LRG1, LRG
Application Dilute:
Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.
Application Notes:
Cross-Reactivity: Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage,it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA,5% HSA,10% FBS or 5% Trehalose),and aliquot the reconstituted protein solution to minimize free-thaw cycles., ResearchArea: Biosimilar Drug Targets
Recombinant Human LRG1(P133S) Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.
* VAT and and shipping costs not included. Errors and price changes excepted
